We're contacting Genzyme via friends of friends. Your question is valid. I wouldn't expect Genzyme to do much unless there's profit (or at least little cost)

We're contacting Genzyme via friends of friends. Your question is valid. I wouldn't expect Genzyme to do much unless there's profit (or at least little cost) involved. Fortunately, Genzyme might not need to do much, since the enzyme is already in production, but for laboratory rather than human use. I'll admit I don't know much more will be required to take what they injected into mice to the point where we can inject it into Bertrand. We're learning on the fly. Since Genzyme holds the patent, I think we'll at least need their permission to use it in a clinical setting. We're also actively searching for other NGLY1 patients. There may yet be a market. We're also investigating other possible clinical applications of N-Glycanase 1. My own early research indicates that it may help in cases of severe jaundice--a much larger market. I'm optimistic that we can get Genzyme's attention.